CTRI/2023/08/056321招募中1 期
A Phase 1, Open Label, Dose Escalation, Dose Expansion, MulticenterStudy Evaluating the Safety, Pharmacokinetics and Pharmacodynamicsof Oral AUR108 in Patients with Relapsed Advanced Lymphomas(ASHA-1) - ASHA-1
Aurigene Oncology Limited(Subsidiary of Dr. Reddy’s Laboratories Limited)0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Males or females = 18 years of age
- •2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1
- •3. Acceptable bone marrow and organ function at screening as described below:
- •a. ANC = 1000/µL (without WBC growth factor support)
- •b. Platelet count = 75,000/µL without transfusion support
- •c. Hemoglobin = 9 g/dL (Transfusion is allowed to achieve this Hb)
- •d. Total Bilirubin = 1.5 x ULN; (Patients with known Gilbert’s syndrome are allowed with a Total Bilirubin = 2.5 x ULN)
- •e. AST (SGOT) = 3 x ULN (= 5 × ULN if known liver metastases)
- •f. ALT (SGPT) = 3 x ULN (= 5 × ULN if known liver metastases)
- •g. Creatinine clearance (CrCl) = 30 mL/min .
- •4. Ability to swallow and retain oral medications
- •5. Histo-pathological diagnosis of a Non-Hodgkin lymphoma or Hodgkin Lymphoma
- •Note: The lymphoma should be either in Stage III or IV according to Lugano classification (Cheson BD et al, 2014) at screening.
- •6. In the case of subjects who have lymphoma for which high-dose chemotherapy and autologous stem cell transplantation (HDASCT) is considered a standard curative therapy, eligibility for this study requires that the subject’s disease has relapsed after HDASCT, that the subject is not eligible for HD-ASCT, or that the subject has refused HD-ASCT.
- •7. In the case of subjects who have lymphoma for which CAR-T therapy is considered a standard therapy, eligibility for this study requires that the subject’s disease has relapsed after CAR-T, or that the subject has refused CAR-T, or that the CAR-T therapy is not accessible to the patient.
- •8. Evidence of measurable disease as per Lugano Criteria for Lymphoma (Cheson BD et al, 2014).
- •9. Standard curative measures do not exist, and patient must have exhausted all effective therapies, available locally.
- •a. At a minimum, the patients must have received at least 2 prior lines of systemic therapies. These systemic therapies could be either in the stage II, III or IV.
- •b. Any cancer patient with access to any effective therapy must not be enrolled
排除标准
- •1. Systemic anti-cancer therapy, such as chemotherapy, or biological therapy, immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from the Cycle 1 Day 1 of the study.
- •2. Presence of an acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade = 1, as determined by NCI CTCAE v 5.0
- •3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial)
- •4. Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
- •5. Patients with cutaneous lymphomas, mycosis fungoides (MF) or Sézary syndrome (SS).
- •6. Primary CNS lymphoma
- •7. Known symptomatic or untreated or recently treated (= 6 months of screening) central nervous system (CNS) lymphoma. Patients with previously treated ( > 6 months of screening) CNS lymphoma and are now stable and asymptomatic, from CNS perspective, are allowed
- •8. Patients with lymphoma that requires immediate cytoreductive therapy
- •9. Patients with low-grade lymphoma that does not meet conventional criteria for requiring treatment.
- •10. Patients on the drugs which are sensitive substrates of CYP2C8 and cannot be discontinued at least one week prior to Cycle 1 Day 1.
- •11. Patients on the drugs which are sensitive substrates of either Pglycoprotein (P-gp) or breast cancer resistance protein (BCRP) and cannot be discontinued at least one week prior to Cycle 1
- •12. Major surgery = 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia)
- •13. Active infection requiring systemic therapy.
- •Note: Prophylactic use of antibiotics is allowed. Any infection detected during screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
- •14. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness
- •15. Known active or chronic hepatitis B (HbsAg +ve) or hepatitis C infection (HCV antibody +ve)
- •16. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.
- •17. Uncontrolled congestive heart failure (New York Heart Association (NYHA) Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1
- •18. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
- •19. QTc (Bazzett) interval >460 ms on ECG at screening and/or at Cycle 1 Day 1 pre-dose.
- •20. Uncontrolled intercurrent illness including, but not limited to,symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g. renal, hepatic, hematologic,
- •gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or clinically significant laboratory / ECG
- •abnormalities at screening, any or a combination of illnesse
研究者
相似试验
招募中
1 期
A Phase I clinical trial evaluating the Safety, Tolerability, and Efficacy of Oral AUR107 in Patients with Advanced CancerCTRI/2023/05/052954Aurigene Oncology Limited
招募中
1 期
A Phase I, Open label, First in Human Dose-Escalation and Dose Expansion StudyCTRI/2022/09/046061Aurigene Discovery Technologies Limited
已完成
不适用
A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic MalignanciesBlood cancerLeukaemias10024324NL-OMON41336Epizyme, Inc.10
进行中（未招募）
1 期
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsJPRN-jRCT2031210676Kawai Norisuke240
招募中
1 期
Phase I study of MGY825 in patients with advanced non-small cell lung canceradvanced non-small cell lung cancerJPRN-jRCT2031220278Yamauchi Kyosuke12